Metformin to improve heart function after LVAD implant
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if metformin, a medicine commonly used for diabetes, can help improve heart function in people who have a mechanical heart pump (LVAD). You may be able to join if you are between 18 and 75, have a continuous-flow LVAD, and have a condition called insulin resistance (where your body doesn't use insulin well) but your blood sugar levels are well-controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a continuous-flow LVAD (a type of heart pump like HeartMate 3 or HVAD).
- Your body has insulin resistance (a condition where insulin doesn't work as well as it should).
- Your average blood sugar over the past few months (HbA1c) is 6.5% or lower.
- You do not have type 1 diabetes or type 2 diabetes with high blood sugar.
- You are not currently taking any medicines to lower blood sugar, including insulin or pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This study tests whether a small sensor (CardioMEMS) implanted in the lung artery can help doctors better manage LVAD settings and reduce hospital visits. It is for people who already have a HeartMate 3 heart pump and are stable enough to go home.
This study tests a program that provides extra support and care planning for people who have been living with a heart pump (LVAD) for at least a year. The goal is to help you feel better and manage your health.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
This trial tests a new left-ventricular assist device (LVAD) called BrioVAD for people with advanced heart failure who are not getting enough benefit from medicines. If you qualify, the device is implanted to help your heart pump blood.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.